AR 1003
Alternative Names: AR-1003Latest Information Update: 23 Jul 2025
At a glance
- Originator AriBio
- Class Antidementias; Small molecules
- Mechanism of Action G protein-coupled receptor agonists; Purinergic P1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Alzheimer's disease
- Discontinued COVID 2019 infections; Sepsis
Most Recent Events
- 21 Jul 2025 Phase-I clinical trials in Alzheimer's disease (unspecified route) prior to July 2025 (AriBio pipeline, July 2025)
- 25 Sep 2023 Discontinued - Preclinical for COVID-2019 infections in South Korea (unspecified route) (AriBio pipeline, September 2023)
- 25 Sep 2023 Discontinued - Preclinical for Sepsis in South Korea (unspecified route) (AriBio pipeline, September 2023)